CA2061567A1 - Use of hyaluronic acid to repair ischemia reperfusion damage - Google Patents

Use of hyaluronic acid to repair ischemia reperfusion damage

Info

Publication number
CA2061567A1
CA2061567A1 CA2061567A CA2061567A CA2061567A1 CA 2061567 A1 CA2061567 A1 CA 2061567A1 CA 2061567 A CA2061567 A CA 2061567A CA 2061567 A CA2061567 A CA 2061567A CA 2061567 A1 CA2061567 A1 CA 2061567A1
Authority
CA
Canada
Prior art keywords
hyaluronic acid
repair
ischemia reperfusion
reperfusion damage
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2061567A
Other languages
French (fr)
Other versions
CA2061567C (en
Inventor
Rudolf E. Falk
Samuel Simon Asculai
Ehud Shmuel Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
NORPHARMCO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORPHARMCO Inc filed Critical NORPHARMCO Inc
Priority to CA002061567A priority Critical patent/CA2061567C/en
Priority to SG1996002901A priority patent/SG49654A1/en
Priority to EP93301230A priority patent/EP0557118A1/en
Publication of CA2061567A1 publication Critical patent/CA2061567A1/en
Priority to US08/200,309 priority patent/US5674857A/en
Application granted granted Critical
Publication of CA2061567C publication Critical patent/CA2061567C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid

Abstract

A pharmaceutical composition comprising an effective non-toxic amount of hyaluronic acid (HA) and or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and units of HA in association with a suitable diluent or pharmaceutically acceptable carrier for use in treating ischemia damage in tissue.
CA002061567A 1992-02-20 1992-02-20 Use of hyaluronic acid to repair ischemia reperfusion damage Expired - Lifetime CA2061567C (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002061567A CA2061567C (en) 1992-02-20 1992-02-20 Use of hyaluronic acid to repair ischemia reperfusion damage
SG1996002901A SG49654A1 (en) 1992-02-20 1993-02-19 The use of hyaluronic acid to repair ischemia reperfusion damage
EP93301230A EP0557118A1 (en) 1992-02-20 1993-02-19 The use of hyaluronic acid to repair ischemia reperfusion damage
US08/200,309 US5674857A (en) 1992-02-20 1994-02-23 Use of hyaluronic acid to repair ischemia reperfusion damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002061567A CA2061567C (en) 1992-02-20 1992-02-20 Use of hyaluronic acid to repair ischemia reperfusion damage

Publications (2)

Publication Number Publication Date
CA2061567A1 true CA2061567A1 (en) 1993-08-21
CA2061567C CA2061567C (en) 1998-02-03

Family

ID=4149301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002061567A Expired - Lifetime CA2061567C (en) 1992-02-20 1992-02-20 Use of hyaluronic acid to repair ischemia reperfusion damage

Country Status (4)

Country Link
US (1) US5674857A (en)
EP (1) EP0557118A1 (en)
CA (1) CA2061567C (en)
SG (1) SG49654A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
US5585361A (en) * 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
US5591724A (en) * 1995-02-14 1997-01-07 Bioniche Inc. Method for treating the urinary bladder and associated structures using hyaluronic acid
JP4627580B2 (en) * 2000-06-08 2011-02-09 生化学工業株式会社 Liver disease treatment
WO2002035929A1 (en) * 2000-11-03 2002-05-10 Vitrolife Ab Evaluation and preservation solution
JP4537057B2 (en) 2001-08-14 2010-09-01 テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and treatment
US9241735B2 (en) 2003-12-05 2016-01-26 Onset Medical Corporation Expandable percutaneous sheath
CA2560200A1 (en) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
US20060135962A1 (en) 2004-09-09 2006-06-22 Kick George F Expandable trans-septal sheath
US7892203B2 (en) 2004-09-09 2011-02-22 Onset Medical Corporation Expandable transluminal sheath
US8337518B2 (en) 2006-12-20 2012-12-25 Onset Medical Corporation Expandable trans-septal sheath
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
JP6091415B2 (en) * 2010-10-07 2017-03-08 ナショナル チェン クン ユニバーシティー Use of hyaluronan to promote ischemic limb blood flow in diabetes
IN2014MN01886A (en) 2012-04-18 2015-07-10 Univ Ramot
EP3160448A4 (en) 2014-06-26 2018-11-14 Ramot at Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
CN112972490B (en) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 Application of hyaluronic acid in preparing medicine for preventing or treating iron death related diseases

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IT1229075B (en) * 1985-04-05 1991-07-17 Fidia Farmaceutici Topical compsn. contg. hyaluronic acid deriv. as vehicle
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
IN163192B (en) * 1983-10-11 1988-08-20 Fidia Spa
NO161573C (en) * 1983-11-25 1989-08-30 Miles Inc PROCEDURE FOR THE PREPARATION OF HYALURONIC ACID.
CA1295796C (en) * 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
JPS6117A (en) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd Mucopolysaccharide-type cancer-metastatis suppressing agent
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP0187703B1 (en) * 1985-01-11 1992-08-05 Teijin Limited Sustained release preparation
US4784990A (en) * 1985-01-18 1988-11-15 Bio-Technology General Corporation High molecular weight sodium hyaluronate
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
EP0207638B1 (en) * 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584606A1 (en) * 1985-07-12 1987-01-16 Dropic USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE
IN166447B (en) * 1985-11-27 1990-05-12 Ethicon Inc
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
JP2604135B2 (en) * 1986-02-28 1997-04-30 ライオン株式会社 Oral bone disease treatment
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
IT1213301B (en) * 1986-07-14 1989-12-20 Zambon Spa COMPOSITIONS FOR THE TREATMENT OF SYNDROMES FROM ISCHEMIA AND REPERFUSION
IT1198449B (en) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
ZA878877B (en) * 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
GB8706052D0 (en) * 1987-03-13 1987-04-15 Medical Research Int Therapeutic compositions
ATE129254T1 (en) * 1987-03-19 1995-11-15 Arthropharm Pty Ltd ANTI-INFLAMMATORY AGENTS AND COMPOSITIONS.
EP0285357A3 (en) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
US4931460A (en) * 1987-09-17 1990-06-05 E. R. Squibb & Sons, Inc. Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US4968671A (en) * 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
DK505588D0 (en) * 1988-02-26 1988-09-09 Jesper Hamburger MEDIUM AND USE OF SAME
JPH01287041A (en) * 1988-05-13 1989-11-17 Rooman Kogyo:Kk Sustained release preparation
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
WO1991015215A1 (en) * 1990-03-30 1991-10-17 Biomedical Frontiers, Inc. Fluid resuscitation
US5099012A (en) * 1990-12-11 1992-03-24 Eastman Kodak Company Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
DE19538814C2 (en) * 1995-10-18 1998-07-09 Obermaier Geb Ohg Foot massager

Also Published As

Publication number Publication date
US5674857A (en) 1997-10-07
EP0557118A1 (en) 1993-08-25
CA2061567C (en) 1998-02-03
SG49654A1 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
CA2061567A1 (en) Use of hyaluronic acid to repair ischemia reperfusion damage
CA2145527A1 (en) Tissue protective and regenerative compositions
EP0831777A4 (en)
NZ240936A (en) Alkoxy-substituted 1-phenyl-isoquinoline derivative and pharmaceutical compositions
GB2260079B (en) Pharmaceutical composition containing felbinac
EP0731712A4 (en) Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
NZ335146A (en) N-(N'-substituted glycyl)-2-cyanopyrrolidine derivatives and medicaments
MD921G2 (en) Arylpropionic derivatives, process for preparation and the pharmaceutical composition on base thereof
CA2132416A1 (en) Use of transglutaminase inhibitor for the treatment of scar tissue
CA2307788A1 (en) 2-halo-6-o-substituted ketolide derivatives
CA2042972A1 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
CA2007507A1 (en) Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
CA2135614A1 (en) Use of urodilatin in pulmonary and bronchial diseases
CA2079205A1 (en) Use of Hyaluronic Acid and Forms to Prevent Arterial Restenosis
CA2061907A1 (en) Treatment of ocular hypertension with a synergistic combination
CA2176392A1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
MY133222A (en) Method of treating glaucoma and ischemic retinopathy
AU4847390A (en) Fluorinated flavone acetic acid
CA2176376A1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy
EP0387074A3 (en) Novel oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
CA2120045A1 (en) Use of Hyaluronic Acid and Forms to Prevent Arterial Restenosis
CA2106695A1 (en) Hyaluronic Acid and Forms to Prevent Arterial Restenosis

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry